CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients

Ada A. O., Kunak S. C., Hancer F., Bilgen S., SÜZEN H. S., Alpar S., ...Daha Fazla

NEOPLASMA, cilt.57, sa.6, ss.512-521, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 6
  • Basım Tarihi: 2010
  • Doi Numarası: 10.4149/neo_2010_06_512
  • Dergi Adı: NEOPLASMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.512-521
  • Anahtar Kelimeler: Cytochrome P-450, glutathione S-transferase, non small cell lung cancer, polymorphism, survival, S-TRANSFERASE-PI, HUMAN CYTOCHROME-P450 1B1, GERM-LINE POLYMORPHISMS, BREAST-CANCER, POPULATION FREQUENCY, P1 POLYMORPHISMS, ORAL-CANCER, ASSOCIATION, RISK, METABOLISM
  • Ankara Üniversitesi Adresli: Evet

Özet

Several polymorphisms in cytochrome P-450s (CYP)s and Glutathione S-transferases (GST)s have been reported to be associated with survival rates of patients with non-small cell lung cancer (NSCLC) but the studies in this regard are scarce and the results are contradictory. In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival. Of the studied GYP and GST polymorphisms only GSTP1 exon 6 variant significantly altered (improved) the survival compared to wild type (p=0.036) with median survival of 22.2 months and 16.1 months, respectively. Multivariate analysis also revealed a significant reduction of adjusted hazard ratio of death associated only with the GSTP1 exon 6 variant genotype of 0.45(95% confidence interval (95% CI), 0.23-0.89,p=0.022). These results show that the GSTP1 exon 6 variant genotype is associated with improved survival in the patients with advanced NSCLC.